Brazil's health regulator Anvisa approved the registration of the second generic semaglutide medication on Monday [1].
The approval is expected to lower the cost of treatments for type-2 diabetes and obesity by increasing the number of therapeutic options available to patients [4, 6].
Agência Nacional de Vigilância Sanitária (Anvisa) granted the approval to Germed Farmacêutica [1]. The new product is a 1.34 mg/mL injectable solution [4]. An Anvisa representative said the new product uses the Ozivy injection pen as its reference [6].
This decision follows a rapid expansion of the generic market for the active ingredient. A first generic semaglutide from EMS was approved on Aug. 17, 2026 [5]. The introduction of a second generic within one week suggests a shifting landscape for weight-loss and diabetes medications in the country [4].
"The approval expands options to lower the cost of the active ingredient consecrated by Ozempic and Wegovy," an Anvisa spokesperson said [2].
Semaglutide is the primary component in several high-profile medications used to manage blood sugar levels and reduce body weight. By allowing generic versions, the regulator aims to reduce the financial burden on patients who require long-term treatment [4, 6].
Anvisa said that it approved the registration of the second generic semaglutide drug in Brazil [1]. The agency, headquartered in Brasília, oversees the safety and efficacy of all pharmaceutical products entering the Brazilian market [1, 2].
“The approval expands options to lower the cost of the active ingredient consecrated by Ozempic and Wegovy.”
The rapid approval of two generic semaglutide versions within a single week indicates a strategic push by Brazilian regulators to break the monopoly of expensive brand-name GLP-1 receptor agonists. By increasing competition among pharmaceutical providers like Germed Farmacêutica and EMS, Brazil is positioning itself to make obesity and diabetes treatments more accessible to a broader socio-economic demographic, potentially reducing long-term public health costs associated with these chronic conditions.
